ICI was moved earlier in the therapeutic pathway following the landmark PACIFIC randomised trial3, which showed that the rate of distant failure in patients treated with potentially-curable unresectable stage III NSCLC treated with definitive chemoradiation was significantly reduced by adjuvant anti-PDL1 antibody therapy given after completion of locoregional therapy, presumably by eradicating micrometastases beyond the radiotherapy treatment volume. This evidence concerns the gene CD274 and non-small cell lung carcinoma.